VANCOUVER, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for targeted treatment of neuropsychiatric disorders, epilepsy and pain, today announced that The Nasdaq Stock Market LLC has approved the listing of the Company’s common stock on The…


Previous articleU.S. FDA Approves Nova Mentis Orphan Drug Application
Next articleCOMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder